Clinical Trials Browser

OTHER × Neuroectodermal Tumors, Primitive × Radiotherapy × Clear all

Neuroectodermal Tumors, Primitive, Pyloric Stenosis, Hypertrophic

NCT02066220 2025-12-04

International Society of Paediatric Oncology (SIOP) PNET 5 Medulloblastoma

Phase 2/3 Active not recruiting

360 enrolled

CNS

Brain Neoplasms, Medulloblastoma, Neuroectodermal Tumors, Primitive

NCT01878617 2025-11-13

A Clinical and Molecular Risk-Directed Therapy for Newly Diagnosed Medulloblastoma

Phase 2 Active not recruiting

660 enrolled

CNS

Brain Neoplasms, Medulloblastoma, Infratentorial Neoplasms, Neuroectodermal Tumors, Primitive

NCT00031798 2021-09-09

Methylphenidate to Improve Quality of Life in Patients Undergoing Radiation Therapy for Brain Tumors

Phase 3 Terminated

CNSSarcoma

Astrocytoma, Brain Neoplasms, Depression, Ependymoma, Fatigue, Glioblastoma, Glioma, Meningioma, Oligodendroglioma, Central Nervous System Neoplasms, Neuroectodermal Tumors, Primitive, Glioma, Subependymal, Gliosarcoma

NCT01977677 2018-10-23

Plerixafor After Radiation Therapy and Temozolomide in Treating Patients With Newly Diagnosed High Grade Glioma

Phase 1/2 Completed

30 enrolled 11 charts

CNSSarcoma

Glioblastoma, Glioma, Medulloblastoma, Pinealoma, Neuroectodermal Tumors, Primitive, Gliosarcoma

NCT00003478 2013-02-20

Radiolabeled Monoclonal Antibody Therapy in Treating Patients With Primary Brain Tumors

Phase 1/2 Completed

10 enrolled

CNSSarcoma

Astrocytoma, Brain Neoplasms, Ependymoma, Glioblastoma, Glioma, Medulloblastoma, Oligodendroglioma, Central Nervous System Neoplasms, Neuroectodermal Tumors, Primitive, Gliosarcoma

Clinical Trials

PNOC031

International Society of Paediatric Oncology (SIOP) PNET 5 Medulloblastoma

A Clinical and Molecular Risk-Directed Therapy for Newly Diagnosed Medulloblastoma

Methylphenidate to Improve Quality of Life in Patients Undergoing Radiation Therapy for Brain Tumors

Plerixafor After Radiation Therapy and Temozolomide in Treating Patients With Newly Diagnosed High Grade Glioma

Radiolabeled Monoclonal Antibody Therapy in Treating Patients With Primary Brain Tumors